Correlation Between GH Research and Eliem Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both GH Research and Eliem Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining GH Research and Eliem Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between GH Research PLC and Eliem Therapeutics, you can compare the effects of market volatilities on GH Research and Eliem Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in GH Research with a short position of Eliem Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of GH Research and Eliem Therapeutics.

Diversification Opportunities for GH Research and Eliem Therapeutics

-0.16
  Correlation Coefficient

Good diversification

The 3 months correlation between GHRS and Eliem is -0.16. Overlapping area represents the amount of risk that can be diversified away by holding GH Research PLC and Eliem Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eliem Therapeutics and GH Research is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on GH Research PLC are associated (or correlated) with Eliem Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eliem Therapeutics has no effect on the direction of GH Research i.e., GH Research and Eliem Therapeutics go up and down completely randomly.

Pair Corralation between GH Research and Eliem Therapeutics

Given the investment horizon of 90 days GH Research PLC is expected to generate 0.99 times more return on investment than Eliem Therapeutics. However, GH Research PLC is 1.01 times less risky than Eliem Therapeutics. It trades about 0.14 of its potential returns per unit of risk. Eliem Therapeutics is currently generating about -0.29 per unit of risk. If you would invest  806.00  in GH Research PLC on August 29, 2024 and sell it today you would earn a total of  104.00  from holding GH Research PLC or generate 12.9% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy90.91%
ValuesDaily Returns

GH Research PLC  vs.  Eliem Therapeutics

 Performance 
       Timeline  
GH Research PLC 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days GH Research PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.
Eliem Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Eliem Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.

GH Research and Eliem Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with GH Research and Eliem Therapeutics

The main advantage of trading using opposite GH Research and Eliem Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if GH Research position performs unexpectedly, Eliem Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eliem Therapeutics will offset losses from the drop in Eliem Therapeutics' long position.
The idea behind GH Research PLC and Eliem Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Other Complementary Tools

Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios